Cambridge, MA-based drug developer CombinatoRx announced today that it has changed its name to Zalicus to better reflect its assets and focus, following its merger last year with Vancouver-based Neuromed Pharmaceuticals. The company garnered its first drug approval earlier this year for the pain treatment hydromorphone HCL (Exalgo), which is being marketed by healthcare products company Covidien (NYSE: [[ticker:COV]]). “Our new name reflects the Company’s transformation into a biopharmaceutical company with product revenues, two powerful and differentiated drug discovery platforms, a pipeline of product candidates and proven drug development expertise focused on the treatment of pain and inflammation,” announced Mark Corrigan, president and CEO of Zalicus (NASDAQ: [[ticker:ZLCS]]), which started trading under its new stock symbol today.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
